Kameel D. Farag serves as Executive at Akari Therapeutics Plc, where they oversee executive responsibilities. Since joining the company, Kameel D. Farag has executed 4 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on Jan 5, 2026 involved receiving (via award) 57,500 shares valued at $0.
Kameel D. Farag currently holds 57,500 shares of Akari Therapeutics Plc (AKTX), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Kameel D. Farag has been a net neutral trader of AKTX stock. They have purchased $0 and sold $0 worth of shares.
Kameel D. Farag's most recent insider trade was on Jan 5, 2026, when they sold 57,500 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted
| $0.75 |
| Discretionary |
| Nov 1, 2025 | AKTX | $20.0K | Award | 26,619 | $0.75 | Discretionary |
| Oct 22, 2025 | AKTX | $4.6K | Award | 6,277 | $0.74 | Discretionary |